Search

Your search keyword '"Barnes, Jeffrey A."' showing total 993 results
Start Over Author "Barnes, Jeffrey A."
993 results on '"Barnes, Jeffrey A."'

1. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium

Author

Han, Jessy Xinyi, Koh, Min Jung, Boussi, Leora, Sorial, Mark, McCabe, Sean M., Peng, Luke, Singh, Shambhavi, Eche-Ugwu, Ijeoma Julie, Gabler, Judith, Fernandez Turizo, Maria J., MacVicar, Caroline T., Garg, Aditya, Disciullo, Alexander, Chopra, Kusha, Lenart, Alexandra, Nwodo, Emmanuel, Barnes, Jeffrey, Koh, Min Ji, Miranda, Eliana, Chiattone, Carlos, Stuver, Robert, Horwitz, Steven M., Merrill, Mwanasha, Jacobsen, Eric, Manni, Martina, Civallero, Monica, Skrypets, Tetiana, Lymboussaki, Athina, Federico, Massimo, Kim, Yuri, Kim, Jin Seok, Cho, Jae Yong, Eipe, Thomas, Shet, Tanuja, Sridhar, Epari, Shetty, Alok, Saha, Saswata, Jain, Hasmukh, Sengar, Manju, Van Der Weyden, Carrie, Prince, Henry Miles, Hamouche, Ramzi, Murdashvili, Tinatin, Foss, Francine, Gentilini, Marianna, Casadei, Beatrice, Zinzani, Pier Luigi, Okatani, Takeshi, Yoshida, Noriaki, Yoon, Sang Eun, Kim, Won-Seog, Panchoo, Girisha, Mohamed, Zainab, Verburgh, Estelle, Alturas, Jackielyn Cuenca, Al-Mansour, Mubarak, Ford, Josie, Cabrera, Maria Elena, Ku, Amy, Bhagat, Govind, Ma, Helen, Sawas, Ahmed, Kariya, Khyati Maulik, Iwasaki, Makoto, Bhanushali, Forum, O’Connor, Owen A., Marchi, Enrica, Shen, Changyu, Shah, Devavrat, and Jain, Salvia

Published
2025
Full Text
View/download PDF

2. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Author

Kumar, Anita, Soumerai, Jacob, Abramson, Jeremy S., Barnes, Jeffrey A., Caron, Philip, Chhabra, Shalini, Chabowska, Maria, Dogan, Ahmet, Falchi, Lorenzo, Grieve, Clare, Haydu, J. Erika, Johnson, Patrick Connor, Joseph, Ashlee, Kelly, Hailey E., Labarre, Alyssa, Lue, Jennifer Kimberly, Martignetti, Rosalba, Mi, Joanna, Moskowitz, Alison, Owens, Colette, Plummer, Sean, Puccio, Madeline, Salles, Gilles, Seshan, Venkatraman, Simkins, Elizabeth, Slupe, Natalie, Zhang, Honglei, and Zelenetz, Andrew D.

Published
2025
Full Text
View/download PDF

3. Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

Author

Topp, Max S., Matasar, Matthew, Allan, John N., Ansell, Stephen M., Barnes, Jeffrey A., Arnason, Jon E., Michot, Jean-Marie, Goldschmidt, Neta, O’Brien, Susan M., Abadi, Uri, Avivi, Irit, Cheng, Yuan, Flink, Dina M., Zhu, Min, Brouwer-Visser, Jurriaan, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, and Crombie, Jennifer L.

Published
2025
Full Text
View/download PDF

4. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Author

Bannerji, Rajat, Arnason, Jon E, Advani, Ranjana H, Brown, Jennifer R, Allan, John N, Ansell, Stephen M, Barnes, Jeffrey A, O'Brien, Susan M, Chávez, Julio C, Duell, Johannes, Rosenwald, Andreas, Crombie, Jennifer L, Ufkin, Melanie, Li, Jingjin, Zhu, Min, Ambati, Srikanth R, Chaudhry, Aafia, Lowy, Israel, and Topp, Max S

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Lymphoma, Cancer, Biotechnology, Clinical Research, Hematology, Immunization, Orphan Drug, Genetics, Rare Diseases, Immunotherapy, Health Disparities, Patient Safety, Lymphatic Research, Minority Health, Vaccine Related, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Aged, Antibodies, Bispecific, Antigens, CD20, Antineoplastic Agents, Cytokine Release Syndrome, Female, Humans, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Male, Middle Aged, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

BackgroundOdronextamab is a hinge-stabilised, fully human IgG4-based CD20 × CD3 bispecific antibody that binds CD3 on T cells and CD20 on B cells. We aimed to evaluate the safety and antitumour activity of odronextamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.MethodsThis single-arm, multicentre, phase 1, dose-escalation and dose-expansion (ELM-1) trial was conducted at ten academic sites across the USA and Germany. Patients aged 18 years or older with CD20-positive relapsed or refractory B-cell malignancies who previously received CD20-directed antibody therapy and who had at least one measurable lesion, and an ECOG performance status of 0 or 1 were included. Patients received intravenous odronextamab, according to a step-up dosing schedule in cycle 1, followed by treatment once per week at target doses ranging from 0·1 mg to 320 mg during cycles 2-4 (each cycle was 21 days). After cycle 4, maintenance treatment occurred every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint of safety was assessed by the incidence of adverse events and dose-limiting toxicities to determine the maximum tolerated dose or phase 2 dose of odronextamab, or both. Preliminary antitumour activity, as measured by objective response rate, was a secondary endpoint. This study is registered with ClinicalTrials.gov, NCT02290951.FindingsFrom Feb 4, 2015, to Sept 25, 2021, 145 heavily pretreated patients (median of 3 (IQR 2-5] previous therapies) were enrolled (94 to the dose-escalation and 51 to the dose-expansion part of the study). The median age of patients was 67·0 years (IQR 57·0-73·0); 101 (70%) were male and 44 (30%) were female; most participants were White (119 [82%]) and not Hispanic or Latino (132 [91%]). 42 (29%) patients received previous CAR T therapy and 119 (82%) were refractory to the last line of therapy. Median duration of follow-up was 4·2 months (IQR 1·5-11·5). During dose escalation, odronextamab was administered up to the maximum dose of 320 mg once per week and no dose-limiting toxicities were observed. The recommended dose for expansion in patients with follicular lymphoma grade 1-3a was 80 mg and was 160 mg for patients with diffuse large B-cell lymphoma. Cytokine release syndrome and neurological treatment-emergent adverse events were predominantly low grade and did not result in treatment discontinuation. The most common grade 3 or worse treatment-emergent adverse events were anaemia (36 [25%]), lymphopenia (28 [19%]), hypophosphataemia (27 [19%]), neutropenia (27 [19%]), and thrombocytopenia (20 [14%]). Serious treatment-emergent adverse events occurred in 89 (61%) of 145 patients; the most frequent were cytokine release syndrome (41 [28%]), pyrexia (11 [8%]), pneumonia (nine [6%]), and infusion-related reaction (six [4%]). Four deaths were considered related to treatment (gastric perforation in a patient with gastric involvement by lymphoma, lung infection, pneumonia, and tumour-lysis syndrome). Objective response rate was 51% (95% CI 42-59; 72 of 142). In patients with follicular lymphoma who received odronextamab doses of 5 mg or higher, the objective response rate was 91% (95% CI 75-98; 29 of 32) and the complete response rate was 72% (95% CI 53-86; 23 of 32). In patients with diffuse large B-cell lymphoma without previous CAR T-cell therapy who received doses of 80 mg or higher, the objective response rate was 53% (eight of 15) and all responses were complete responses. In patients with diffuse large B-cell lymphoma who had previous CAR T-cell therapy and received doses of 80 mg or higher, the objective response rate was 33% (ten of 30) and complete response rate was 27% (eight of 30).InterpretationOdronextamab monotherapy showed a manageable safety profile and encouraging preliminary activity, including durable responses in heavily pretreated patients with B-cell non-Hodgkin lymphoma, supporting further clinical investigation in phase 2 and 3 trials.FundingRegeneron Pharmaceuticals.

Published
2022

8. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines

Author

Gongora, Carlos A., Drobni, Zsofia D., Quinaglia Araujo Costa Silva, Thiago, Zafar, Amna, Gong, Jingyi, Zlotoff, Daniel A., Gilman, Hannah K., Hartmann, Sarah E., Sama, Supraja, Nikolaidou, Sofia, Suero-Abreu, Giselle Alexandra, Jacobsen, Eric, Abramson, Jeremy S., Hochberg, Ephraim, Barnes, Jeffrey, Armand, Philippe, Thavendiranathan, Paaladinesh, Nohria, Anju, and Neilan, Tomas G.

Published
2022
Full Text
View/download PDF

9. Altered expression of hepatic β-adrenergic receptors in aging rats: implications for age-related metabolic dysfunction in liver.

Author

Shi, Yun, Shu, Zhen-Ju, Wang, Hanzhou, Barnes, Jeffrey, Yeh, Chih-Ko, Katz, Michael, Kamat, Amrita, and Ghosh, Paramita

Subjects
G protein-coupled receptor, G protein-coupled receptor serine/threonine kinase, food restriction, hepatocytes, β-arrestin, Age Factors, Aging, Animals, Caloric Restriction, Cell Membrane, Energy Metabolism, G-Protein-Coupled Receptor Kinase 2, G-Protein-Coupled Receptor Kinase 3, Gene Expression Regulation, Glucose, Hepatocytes, Ligands, Lipid Metabolism, Liver, Male, Rats, Inbred F344, Receptors, Adrenergic, beta-1, Receptors, Adrenergic, beta-2, beta-Arrestin 2
Abstract

Increased β-adrenergic receptor (β-AR)-mediated activation of adenylyl cyclase (AC) in rat liver during aging has been linked to age-related increases in hepatic glucose output and hepatosteatosis. In this study, we investigated the expression of β-ARs, individual receptor subtypes, and G protein-coupled receptor (GPCR) regulatory proteins in livers from aging rats. Radioligand-binding studies demonstrated that β-AR density increased by greater than threefold in hepatocyte membranes from senescent (24-mo-old) compared with young adult (7-mo-old) rats and that this phenomenon was blocked by food restriction, which is known to retard aging processes in rodents. Competition-binding studies revealed a mixed population of β1- and β2-AR subtypes in liver membranes over the adult life span, with a trend for greater β2-AR density with age. Expression of both β-AR subtype mRNAs in rat liver increased with age, whereas β2- but not β1-AR protein levels declined in livers of old animals. Immunoreactive β2- but not β1-ARs were preferentially distributed in pericentral hepatic regions. Levels of GRK2/3 and β-arrestin 2 proteins, which are involved in downregulation of agonist-activated GPCRs, including β-ARs, increased during aging. Insofar as sympathetic tone increases with age, our findings suggest that, despite enhanced agonist-mediated downregulation of hepatic β-ARs preferentially affecting the β2-AR subtype, increased generation of both receptor subtypes during aging augments the pool of plasma membrane-bound β-ARs coupled to AC in hepatocytes. This study thus identifies one or both β-AR subtypes as possible therapeutic targets involved in aberrant hepatic processes of glucose and lipid metabolism during aging.

Published
2018

10. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

Author

Haydu, J. Erika, Maron, Jenny S., Redd, Robert A., Gallagher, Kathleen M.E., Fischinger, Stephanie, Barnes, Jeffrey A., Hochberg, Ephraim P., Johnson, P. Connor, Takvorian, R.W., Katsis, Katelin, Portman, Daneal, Ruiters, Jade, Sechio, Sidney, Devlin, Mary, Regan, Connor, Blumenthal, Kimberly G., Banerji, Aleena, Judd, Allen D., Scorsune, Krista J., McGree, Brianne M., Sherburne, Maryanne M., Lynch, Julia M., Weitzman, James I., Lei, Matthew, Kotton, Camille N., Dighe, Anand S., Maus, Marcela V., Alter, Galit, Abramson, Jeremy S., and Soumerai, Jacob D.

Published
2022
Full Text
View/download PDF

11. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

Author

Soumerai, Jacob D, Mato, Anthony R, Dogan, Ahmet, Seshan, Venkatraman E, Joffe, Erel, Flaherty, Kelsey, Carter, Jason, Hochberg, Ephraim, Barnes, Jeffrey A, Hamilton, Audrey M, Abramson, Jeremy S, Batlevi, Connie L, Matasar, Matthew J, Noy, Ariela, Owens, Colette N, Palomba, M Lia, Kumar, Anita, Takvorian, Tak, Ni, Ai, Choma, Morgan, Friedman, Chaya, Chadha, Puja, Simkins, Elizabeth, Ruiters, Jade, Sechio, Sidney, Portman, Daneal, Ramos, Lauren, Nolet, Natascha, Mahajan, Neena, Martignetti, Rosalba, Mi, Joanna, Scorsune, Krista, Lynch, Julia, McGree, Brianne, Hughes, Stephanie, Grieve, Clare, Roeker, Lindsey E, Thompson, Meghan, Johnson, P Connor, Roshal, Mikhail, Huang, Jane, Biondo, Juliana, Wu, Qun, Jacob, Allison, Abdel-Wahab, Omar, and Zelenetz, Andrew D

Published
2021
Full Text
View/download PDF

12. Toxicities and outcome after CD19‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis.

Author

Kaulen, Leon D., Karschnia, Philipp, Doubrovinskaia, Sofia, Abramson, Jeremy S., Martinez‐Lage, Maria, Shankar, Ganesh, Choi, Bryan D., Barnes, Jeffrey A., El‐Jawahri, Areej, Hochberg, Ephraim P., Johnson, P. Connor, Soumerai, Jacob D., Wick, Wolfgang, Maus, Marcela V., Chen, Yi‐Bin, Frigault, Matthew J., and Dietrich, Jorg

Published
2024
Full Text
View/download PDF

14. CAR T Cells in Primary and Secondary CNS Lymphoma (S27.003)

Author

Dietrich, Jorg, primary, Arrillaga-Romany, Isabel, additional, Eichler, April, additional, Forst, Deborah, additional, Gerstner, Elizabeth, additional, Jordan, Justin, additional, Ly, Ina, additional, Plotkin, Scott, additional, Wang, Nancy, additional, Martinez-Lage, Maria, additional, Winter, Sebastian Friedrich, additional, Rejeski, Kai, additional, Tonn, Jorg-Christian, additional, Baumgarten, Louisa vom, additional, Cahill, Daniel, additional, Nahed, Brian, additional, Shankar, Ganesh, additional, Abramson, Jeremy, additional, Barnes, Jeffrey, additional, El-Jawahri, Areej, additional, Hochberg, Ephraim, additional, Johnson, Patrick, additional, Soumerai, Jacob, additional, Takvorian, Ronald, additional, Chen, Yi-Bin, additional, Frigault, Matthew, additional, and Karschnia, Philipp, additional

Published
2024
Full Text
View/download PDF

15. Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study

Author

Pullarkat, Priyanka, Lei, Matthew, Redd, Robert, Ruchi, Rana, Lou, Uvette, Sorial, Mark, Rowen, Brenna, Kim, E. Bridget, Medrano, Andrea, Haydu, J. Erika, Barnes, Jeffrey, Hochberg, Ephraim, Johnson, P. Connor, Takvorian, Ronald, Lynch, Julia, Patterson, Emily, Thorp, Katherine, Sherbourne, Maryanne, McGree, Brianne, Ford, Josie, Nemec, Ronald, Cho, Catherine, Abramson, Jeremy, and Soumerai, Jacob D.

Published
2025
Full Text
View/download PDF

18. McKay Centralizer Algebras

Author

Barnes, Jeffrey M., Benkart, Georgia, and Halverson, Tom

Subjects
Mathematics - Representation Theory, Mathematics - Combinatorics, 05E10, 14E16, 20C05, 16G99
Abstract

For a finite subgroup $G$ of the special unitary group $SU_2$, we study the centralizer algebra $Z_k(G) = End_G(V^{\otimes k})$ of $G$ acting on the $k$-fold tensor product of its defining representation $V= \mathbb{C}^2$. These subgroups are in bijection with the simply-laced affine Dynkin diagrams. The McKay correspondence relates the representation theory of these groups to the associated Dynkin diagram, and we use this connection to show that the structure and representation theory of $Z_k(G)$ as a semisimple algebra is controlled by the combinatorics of the corresponding Dynkin diagram., Comment: 43 pages; Minor changes, final version to appear in Proceedings of the London Mathematical Society

Published
2013
Full Text
View/download PDF

19. Spreadsheet Design: An Optimal Checklist for Accountants

Author

Barnes, Jeffrey N., Tufte, David, and Christensen, David

Abstract

Just as good grammar, punctuation, style, and content organization are important to well-written documents, basic fundamentals of spreadsheet design are essential to clear communication. In fact, the very principles of good writing should be integrated into spreadsheet workpaper design and organization. The unique contributions of this paper are an integration of a review of the literature on spreadsheet design, with the results of a convenience survey of CPAs, and a "Spreadsheet Design Checklist" for pedagogy. The checklist is intended as a reference for use until the student or professional becomes proficient in basic spreadsheet design and organization and the checklist becomes just as "second nature" as creating well-written memoranda.

Published
2009

21. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Author

Karschnia, Philipp, Jordan, Justin T., Forst, Deborah A., Arrillaga-Romany, Isabel C., Batchelor, Tracy T., Baehring, Joachim M., Clement, Nathan F., Gonzalez Castro, L. Nicolas, Herlopian, Aline, Maus, Marcela V., Schwaiblmair, Michaela H., Soumerai, Jacob D., Takvorian, Ronald W., Hochberg, Ephraim P., Barnes, Jeffrey A., Abramson, Jeremy S., Frigault, Matthew J., and Dietrich, Jorg

Published
2019
Full Text
View/download PDF

22. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP

Author

Nemec, Ronald, primary, Scherrer-Crosbie, Marielle, additional, Abramson, Jeremy S., additional, Redd, Robert, additional, Gilman, Hannah K., additional, Ho, Terry, additional, Wu, Jessica, additional, Heemelaar, Julius, additional, Neuberg, Donna, additional, Hochberg, Ephraim P., additional, Barnes, Jeffrey A., additional, Armand, Philippe, additional, Jacobsen, Eric D., additional, Jacobson, Caron A., additional, Kim, Austin I., additional, Friedman, Robb S., additional, LaCasce, Ann S., additional, Neilan, Tomas G., additional, and Soumerai, Jacob D., additional

Published
2024
Full Text
View/download PDF

23. KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes

Author

Assatova, Bimarzhan, primary, Willim, Robert, additional, Trevisani, Christopher, additional, Haskett, Garrett, additional, Kariya, Khyati Maulik, additional, Chopra, Kusha, additional, Park, Sung Rye, additional, Tolstorukov, Michael Yevgeniy, additional, McCabe, Sean M., additional, Duffy, Jessica, additional, Louissaint, Abner, additional, Huuhtanen, Jani, additional, Bhattacharya, Dipabarna, additional, Mustjoki, Satu, additional, Koh, Min Jung, additional, Powers, Foster, additional, Morgan, Elizabeth A., additional, Yang, Lei, additional, Pinckney, Brandy, additional, Cotton, Matthew J., additional, Crabbe, Andrew, additional, Ziemba, Jessica Beth, additional, Brain, Ian, additional, Heavican-Foral, Tayla B., additional, Iqbal, Javeed, additional, Nemec, Ronald, additional, Rider, Anna Baird, additional, Ford, Josie Germain, additional, Koh, Min Ji, additional, Scanlan, Nora, additional, Feith, David J., additional, Loughran, Thomas P., additional, Kim, Won Seog, additional, Choi, Jaehyuk, additional, Roels, Juliette, additional, Boehme, Lena, additional, Putteman, Tom, additional, Taghon, Tom, additional, Barnes, Jeffrey A., additional, Johnson, P. Connor, additional, Jacobsen, Eric D., additional, Greenberg, Steven A., additional, Weinstock, David M., additional, and Jain, Salvia, additional

Published
2024
Full Text
View/download PDF

30. Natural history of the Albany Pine Bush : Albany and Schenectady counties, New York, including a field guide and trail map /

Author

Barnes, Jeffrey K., New York State Biodiversity Research Institute, New York State Museum, New York Botanical Garden, LuEsther T. Mertz Library, Barnes, Jeffrey K., New York State Biodiversity Research Institute, and New York State Museum

Subjects
Albany County, Albany Pine Bush Preserve (Albany, N.Y.), Albany Suburban Area, Maps, Natural history, New York (State), Schenectady County, Trails
Published
2003

33. CTIM-38. NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECONDARY CNS LYMPHOMA AFTER ADOPTIVE IMMUNOTHERAPY WITH CD19-DIRECTED CAR T-CELLS

Author

Karschnia, Philipp, primary, Arrillaga-Romany, Isabel, additional, Eichler, April, additional, Forst, Deborah, additional, Gerstner, Elizabeth, additional, Jordan, Justin T, additional, Ly, Ina, additional, Plotkin, Scott R, additional, Wang, Nancy, additional, Martinez-Lage, Maria, additional, Winter, Sebastian F, additional, Tonn, Joerg-Christian, additional, Rejeski, Kai, additional, von Baumgarten, Louisa, additional, Cahill, Daniel, additional, Nahed, Brian V, additional, Shankar, Ganesh M, additional, Abramson, Jeremy S, additional, Barnes, Jeffrey A, additional, El-Jawahri, Areej, additional, Hochberg, Ephraim P, additional, Johnson, P Connor, additional, Soumerai, Jacob D, additional, Takvorian, Ronald W, additional, Chen, Yi-Bin, additional, Frigault, Matthew J, additional, and Dietrich, Jorg, additional

Published
2023
Full Text
View/download PDF

37. Ibrutinib Maintenance Following Frontline Treatment in Patients with Mantle Cell Lymphoma

Author

Karmali, Reem, primary, Abramson, Jeremy S, additional, Stephens, Deborah M., additional, Barnes, Jeffrey A., additional, Winter, Jane N, additional, Ma, Shuo, additional, Gao, Juehua, additional, Kaplan, Jason, additional, Petrich, Adam M, additional, Mi, Xinlei, additional, Hochberg, Ephraim P., additional, Takvorian, Ronald W., additional, Nelson, Valerie, additional, Gordon, Leo I., additional, and Pro, Barbara, additional

Published
2023
Full Text
View/download PDF

39. Mycosis Fungoides

Author

Goyal, Amrita, Goyal, Kavita, Carter, Joi B., Barnes, Jeffrey A., Nazarian, Rosalynn M., Hoang, Mai P., Piris, Adriano, Kupper, Thomas, Duncan, Lyn McDivitt, Carter, Joi B., editor, Goyal, Amrita, editor, and McDivitt Duncan, Lyn, editor

Published
2015
Full Text
View/download PDF

40. Sézary Syndrome

Author

Goyal, Amrita, Carter, Joi B., Sohani, Aliyah R., Barnes, Jeffrey A., Hoang, Mai P., Duncan, Lyn McDivitt, Carter, Joi B., editor, Goyal, Amrita, editor, and McDivitt Duncan, Lyn, editor

Published
2015
Full Text
View/download PDF

44. Introduction to the B-Cell Lymphomas

Author

Goyal, Amrita, Sohani, Aliyah R., Kovach, Alexandra E., Carter, Joi B., Barnes, Jeffrey A., Duncan, Lyn McDivitt, Carter, Joi B., editor, Goyal, Amrita, editor, and McDivitt Duncan, Lyn, editor

Published
2015
Full Text
View/download PDF

49. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma

Author

Chen, Yi-Bin, Li, Shuli, Fisher, David C., Driscoll, Jessica, Del Rio, Candice, Abramson, Jeremy, Armand, Philippe, Barnes, Jeffrey, Brown, Jennifer, Cutler, Corey, El-Jawahri, Areej, Ho, Vincent T., Hochberg, Ephraim, McAfee, Steven, Takvorian, Ronald, Spitzer, Thomas R., Antin, Joseph H., Soiffer, Robert, and Jacobsen, Eric

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results